- Danish stocks
- Norwegian stocks
- Swedish stocks
- AktieTorget
- A1M Pharma
- Accelerator Nordic
- AlphaHelix
- AroCell
- Biotech-IgG
- Brighter
- Clinical Laserthermia
- Emotra
- Enzymtica
- Eurocine Vaccines
- European Inst. of Science
- IDL Biotech
- Medfield Diagnostics
- MedicPen
- MediRox
- MediRätt
- Micropos Medical
- PharmaLundensis
- Respiratorius
- Rubicon Life Science
- SensoDetect
- WntResearch
- Orasolv
- Senzime
- SPAGO Imaging
- Vivoline Medical
- First North Stockholm
- OMX Stockholm A-F
- OMX Stockholm G-Z
- AktieTorget
- US stocks
- General discussion
- All posts
“The NGAL Test” on Beckman Coulter AU 5822
Acording to an article printed in Clinical Chemistry and Laboratory Medicine an evaluation of The NGAL Test on the Beckman Coulter AU 5822 has been carried out.
A comparison of the results was then made with the ARCHITECT NGAL test from Abbott,
Lets skip to the result. It works just fine, or as the article puts it: “Conclusions: This analytical evaluation attests that the NGAL Test™ has several technical and analytical advantages, including no manual pretreatment, low volume of sample (i.e., 3 μL), fast turnaround time (approx. 10 min), low imprecision, wide dynamic range, optimal linearity.”
But thats old news to the Bioporto beliver,
What does the article tells us besides that?
Well, it states that the test has been made on the brand new AU5800 series, the fastes AU ever. Currently sold in 50 examples in Europe and Asia, and just recently launced on the US marked. (It’s capable of running between 2.000 and 10.000 test pr hour) Its saying something about the intended use of the test.
And I have to say I love the short and clear statement: “Background: The neutrophil gelatinase associated lipocalin (NGAL) has been identified as the most promising biomarker of acute kidney injury (AKI). This study was aimed to evaluate a NGAL immunoassay on Beckman Coulter AU 5822.”
No need to wrap it in.
About Karl M. Bidstrup
Tidligere ejer af Medicoinvestor.com Strategien har gennem mange år været at profitere på etablerede aktier, og brænde det hele af på Bioporto... Sad but true. Kontakt mig på medicoinvestor(A)gmail.com hvis du har en million du ikke ved hvor du skal gemme, så skal jeg nok holde den for dig. 🙂
- Web |
- More Posts(101)
Related posts:
- Will they ever bring the NGAL test to the market? In November 2010, a productmanager from Beckman Coulter Diagnostics said:...
- Zwanziger on Alere’s NGAL test Important highlight from Alere’s Q4 earnings session: “Additionally, in January...
- NGAL and Acute Heart Failure (AHF) According to an article in the European Journal of Heart...
- Abbott ARCHITECT VS. BioSite Triage. In the 2. edition of Clinical and Laboratory Medicine Vol....
2 Responses to “The NGAL Test” on Beckman Coulter AU 5822
Leave a Reply Cancel reply
Ongoing debate
- Lesliejek on Chat transcript regarding the NGAL distr. Agreement with the Wiener Group. (In danish)
- Patrickciz on Chat transcript regarding the NGAL distr. Agreement with the Wiener Group. (In danish)
- Jameskipse on Chat transcript regarding the NGAL distr. Agreement with the Wiener Group. (In danish)
- Rickiehiela on Chat transcript regarding the NGAL distr. Agreement with the Wiener Group. (In danish)
- James Rolitson on Good Discussion on Bronte Capital’s long thesis on Herbalife
[…] relation to the former post, stating that an evaluation of the The NGAL Test on BC 5822, had been carried out, the full text of […]
[…] relation to the former post, stating that an evaluation of the TNT on BC 5822, had been carried out, the full text is now […]